Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case-control study.
Léo PlaçaisStéphane DalleOlivier DereureSabiha TrabelsiSophie DalacDelphine LegoupilHenri MontaudiéJean-Philippe ArnaultJulie De QuatrebarbesPhilippe SaiagFlorence Brunet-PossentiThierry LesimpleEve MaubecFrançois AubinFlorence Granel-BrocardJean-Jacques GrobPierre-Emmanuel StoebnerClara AllayousBastien OrianoCaroline DutriauxLaurent MortierCéleste LebbePublished in: Annals of the rheumatic diseases (2022)
In our study, patients with pAID were at greater risk of all-grade, severe and multiple irAEs, yet had a better 24-month survival than controls. Thus, patients with pAID should be eligible for ICI therapy but benefit from a close monitoring for irAE occurrence, especially during the first months of therapy.